ANN ARBOR, Mich. – January 31, 2012 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that the company will present at the following industry conferences.
- World Cancer Metabolism Summit, being held Feb. 1-2 at the Washington Marriott Hotel in Washington, D.C. Gary D. Glick, Ph.D., founder and chief scientific officer of Lycera Corp. and Werner E. Bachmann professor of chemistry at the University of Michigan, will give a presentation on the company’s ATPase program in a session titled “Autoimmune Disease Modulation through Mitochondrial Bioenergetics” on Thursday, Feb. 2.
- Biophysical Society 56th Annual Meeting, being held Feb. 25-29 at the San Diego Convention Center in San Diego. Dr. Glick will present during the morning symposium, Mitochondrial Respiratory Chain Diseases of the Bioenergetics Subgroup, on the company’s ATPase program in a session titled “Modulating the Mitochondrial F0F1-ATPase as Therapeutic Strategy for Systematic Autoimmunity” on Saturday, Feb. 25.
- ACI’s 16th Advanced Forum on Structuring and Negotiating Life Sciences Collaborative Agreements & Acquisitions, being held Feb. 27-29 at the Millennium UN Plaza Hotel New York in New York City. Julia C. Owens, Ph.D., senior vice president, corporate development and strategy of Lycera Corp., will speak on the panel “Exploring Perspectives of Innovative Small Companies on the Industry’s Prospects for 2012 and Beyond” on Monday, Feb. 27.
About Autoimmune Diseases
Serious autoimmune diseases are a major and growing public health problem. An autoimmune disorder is a condition that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders1, and approximately 50 million Americans, or one in five people, suffer from autoimmune diseases2.
Lycera Corp. is focused on the discovery and development of oral small-molecule immunomodulators for the treatment of patients with autoimmune diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. Lycera is developing drug candidates that target novel therapeutic pathways and that have the potential to be first-in-class with oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents. Lycera has leading expertise in the emerging area of cellular bioenergetics to selectively target and silence pathologically activated cells. The company also has a program targeting the Th17 pathway through the inhibition of RORγt. Lycera’s leadership team and advisors are thought leaders in immunology, inflammation and bioenergetics. The company has core capabilities in medicinal chemistry, discovery research and early stage development. Visit www.lycera.com for more information.
Pure Communications, Inc.
1 Medline Plus, http://www.nlm.nih.gov/medlineplus/ency/article/000816.htm.
2 American Autoimmune Related Diseases Association, http://www.aarda.org/q_and_a.php.